Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial Finance June 2, 2025 Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial Gilead's Trodelvy, with Keytruda, cuts breast cancer risk…
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds Finance June 1, 2025 Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds Blood test-guided treatment with AstraZeneca pill…
Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial Finance June 1, 2025 Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an…
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial Finance May 31, 2025 Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial Gilead's Trodelvy, with Keytruda, cuts breast cancer risk…
Ten-Year APHINITY Data Show Genentech's Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer Finance May 13, 2025 Ten-Year APHINITY Data Show Genentech's Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer Source…
